They made an obvious typo and deleted the pr. I see a real communication disconnect. Maybe the pr team is to blame. Oncosec needs to update their investor pipeline presentation to mimic their website info and pipeline charts to convey the most up-to-date details about trials and all other information. Details are important. They were also going to do an IST with TAVO and Opdivo in melanoma and now no mention of it but it is still listed in the pipeline on the website but not the investor presentation.
News 
Market Data 
Discover 
